Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus azacitidine versus placebo plus azacitidine in previously untreated acute myeloid leukemia ineligible for intensive induction
2016-001466-28Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Venetoclax + azacitidine with Placebo + azacitidine (2 arms). Primary endpoints: Rate of complete remission or complete remission with incomplete marrow recovery and Overall survival. Started Mar 2017; status: active.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2016-001466-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001466-28.